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Abstract: A 55-year-old man had dysphagia of 4-month duration.
Endoscopy revealed a large polypoidal pedunculated blackish mass
located in the lower thoracic esophagus. A barium esophagogram
revealed a lower esophageal mass. Computed tomography revealed
a large polypoidal esophageal mass without any evidence of local
invasion or distant disease. Endoscopic biopsy established the diag-
nosis of melanoma. A radical resection of the esophagus with
three-field lymph nodal dissection was undertaken. The patient made
an uneventful recovery. Histopathology confirmed the diagnosis of
melanoma and positive lymph nodes. Adjuvant chemotherapy was
given. He succumbed to systemic recurrence after 69 months.
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Since the first description in 1906, approximately 250 casesof primary esophageal melanoma have been reported in
the literature.1 Nevertheless, malignant melanoma of the
esophagus as a primary tumor was accepted only after about
60 years, when De la Pava et al.2 demonstrated the presence
of melanocytes in the esophageal mucosa. The presence of
melanocytosis has been implicated as the precursor lesion by
some workers.3,4
These tumors arising from mucosal melanocytes are
known for their aggressive behavior.1,3–6 Despite aggressive
treatment, the prognosis remains dismal.1,3–6 The reported
5-year survival is less than 5% and only about one-third of
the patients survive beyond 1 year.1,3–6 Long-term survival
after radical resection in the present case forms the basis of
this report.
CASE REPORT
An Indian male, aged 55 years, presented with a
4-month history of gradually progressive painless dysphagia.
He was in good health. General physical examination and
systemic examinations were within normal limits. A detailed
dermatological, ocular, and mucus membrane examination
did not reveal any abnormality. Biochemical, hematologic,
and coagulation studies were normal. An upper gastrointes-
tinal endoscopy revealed a large polypoidal pedunculated
blackish mass in the lower thoracic esophagus (Figure 1).
Gastroesophageal junction and stomach were normal. Endo-
scopic biopsy clinched the diagnosis of malignant melanoma.
A barium contrast esophagogram revealed a polypoid
filling defect with nodular outline involving the lower tho-
racic esophagus. The mucosal outline was irregular. Proximal
esophagus was dilated with hold up of the contrast. A con-
trast-enhanced computerized tomogram of the chest revealed
a well-defined heterogenous soft tissue density, an intraluminal
lesion measuring 5  6 cm in the mid-thoracic and lower
thoracic esophagus. Fat planes with the adjacent viscera were
maintained (Figure 1). There was no evidence of distant disease.
A right posterolateral thoracotomy revealed a 9 4-cm
mass lesion occupying the mid-thoracic and lower thoracic
esophagus. The esophagus could be separated easily from the
adjacent viscera. The patient underwent esophagectomy
and three-field lymphadenectomy in a standard fashion.
The gastrointestinal continuity was restored using a gastric
conduit through the posterior mediastinal route.
Grossly, the specimen revealed an 8  4  3-cm,
irregular, lobulated, polypoidal, and brownish black mass
occupying the mid-esophagus and lower esophagus (Figure
2A). Microscopically, malignant cells formed confluent
masses within the tumor with abundant pigment deposition.
Many clusters of cells were also seen infiltrating the overly-
ing epithelium. The tumor cells showed S-100 positivity
(Figures 2B–D). Hence, a diagnosis of malignant melanoma,
possibly originating from the esophagus, was confirmed. Four
of the 42 lymphnodes showed evidence of tumor deposits.
The patient made an uneventful recovery. A postoper-
ative adjuvant chemotherapy of dacarbazine (800 mg/m2 on
day 1), cisplatin (30 mg/m2 on days 2 to 5), and vinblastine
(1.6 mg/m2 on days 1 to 5) was administered intravenously
(IV). The cycles were repeated every 4 weeks, and a total of
six cycles were administered. The patient remained disease-
free for 66 months as evidenced by periodic imaging and
endoscopic examinations. Subsequently, he developed vis-
ceral (liver) metastasis and succumbed to recurrent disease
after 69 months.
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DISCUSSION
Primary malignant melanoma of the esophagus is a rare
disease, which accounts for 0.1 to 0.2% of the esophageal
neoplasm.3,4 Li et al.5 in their hospital registry of about three
decades reported seven cases of primary esophageal melanoma.
Patients usually present with dysphagia of short dura-
tion. The lesion is most often located in the middle and lower
thirds of the esophagus, probably because of the greater
concentration of melanocytes in this region.7 An upper gas-
trointestinal endoscopy reveals a tumor mass in the esopha-
gus. Suzuki et al.8 detected early stage melanoma in two
patients on endoscopic examination. A contrast esophago-
gram can reveal a large polypoid filling defect with or without
the evidence of mucosal destruction. A computerized tomo-
FIGURE 1. Left, Endoscopic examination of the esophagus showing a large polypoidal mass in the esophagus. Note the
brownish pigmentation of the mass as compared to the surrounding mucosa. Right, CECT chest at the level of inferior
pulmonary vein showing a mass lesion occupying the esophagus. The lumen is chinked. A fat plane with aorta is well
preserved. CECT, contrast-enhanced computerized tomogram.
FIGURE 2. Gross polypoidal black mass
with narrow pedicle (A), multiple foci of
rounded masses of neoplasic cells in the
basal layer of squamous epithelium (B),
large confluent foci of tumor cells in the
deeper portion (C), and S-100 positivity in
the tumor cells (D).
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gram of the chest and the abdomen can illicit an esophageal
mass.9 Endosonogram shows the tumors to be of variable
ecogenecity.10 The incidence of the periesophageal lymph
nodal metastasis is as high as up to 66%; however, it is
unrelated to the depth of tumor invasion.3,4,6
On the basis of standard histologic examination, biopsy
specimens are occasionally misdiagnosed as poorly differen-
tiated carcinoma in the absence of melanin granules.11 Pre-
operative diagnosis can be established in only 54% of the
cases.3,4 This mandates the use of special stains such as
HMB-45 antibody, S-100 protein, and neuron-specific eno-
lase.3,4,11 Grossly, the lesion may appear polypoidal and is
covered with intact mucosa without ulceration. The presence of
satellite tumor nodules have been reported in upto 12% of
patients.3,4 The lesions are mostly pigmented, but nonpigmented
amelanotic variety accounts for in 10 to 25% of the cases.11
Primary malignant melanoma of the esophagus has
extremely poor prognosis with a mean survival of 13.4
months from diagnosis.1,3–5 The poor prognosis is due to
the aggressive biologic behavior, advanced stage at pre-
sentation, and lack of effective therapy. Hematogenous
and lymph node metastases are common with 30 to 40% of
patients having clinical evidence of metastatic disease at
the time of diagnosis.1,3,4,8
Over the years, radical resection for esophageal cancer
has gained popularity. Volpin et al.6 in a thorough MEDLINE
research of 25 cases of esophageal melanoma, in which
patients underwent radical surgery, calculated a 5-year sur-
vival of 37%. In a series of seven cases of primary malignant
melanoma of the esophagus, median survival of 8 months
was achieved with varied therapeutic strategies.5 Neverthe-
less, one of the patients survived as long as 17 years, which
is probably the longest reported survival in this disease.5
Suzuki et al.8 described the detection of early stage melanoma
treated by esophagectomy, and they could achieve long-term
survival. In all the patients surviving beyond 5 years, surgical
extirpation of the tumor had been the main stay of treat-
ment.5,6,8 The present patient also survived beyond 5 years.
A few of the reports mention the use of chemotherapy,
radiotherapy, hormone therapy, and immunotherapy in the
adjuvant and neoadjuvant setting.12 The role of systemic
chemotherapy in adjuvant therapy is not well defined. Nao-
moto et al.12 reported a reduction of the tumor size to 70%
using neoadjuvant DTIC-based chemotherapy. Nevertheless,
the patients treated by chemotherapy, immunotherapy, and
endocrine therapy are very few to advocate any recommen-
dations. The role of radiotherapy is also not well defined.
Because of the lack of conclusive evidence, systemic chemo-
therapy was given in the present case in view of positive
lymph nodes.
Approximately 85% of the patients die with dissemi-
nated disease. The most common sites involved at autopsy
are the liver (39.3%), mediastinum (34.4%), lungs (24.6%),
pleura (19.7%), supraclavicular lymph nodes (19.7%), peri-
toneum (14.8%), brain (13.1%), kidneys, and adrenals
(11.5%), although no site is immune.1,3–6 Likewise, the
present case developed systemic metastasis after 66 months.
Thus, primary malignant melanoma is a rare, aggres-
sive tumor of the esophagus, which should be regarded as a
potentially systemic disease at diagnosis. Surgical extirpation
remains the mainstay of treatment. Although, overall prog-
nosis of the condition is poor, long-term survival can be
achieved by radical resection in selected cases. The role of
adjuvant and neoadjuvant therapy is not well defined.
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